[News Space=Reporter seungwon lee] Global biopharmaceutical company Medytox (CEO Jeong Hyeon-ho) announced on the 29th that it had carried out various promotional activities, including attending the international academic conference 'ICLAS (International Conference of Laser, Aesthetic medicine and Surgery) 2025' held in Bangkok, Thailand for two days from the 25th to the 26th, and revealing the plan to launch products approved at the end of last year in the first half of the year.

'ICLAS 2025', held for the fifth time this year, is an international academic conference co-hosted by the Korean Society of Laser Dermatology and Hair Loss and the Korean Society of Aesthetic Plastic Surgery Laser. This event was a great success with many global medical professionals and industry professionals in attendance.

Medytox actively carried out marketing activities, including setting up a large booth and holding a large-scale promotional event with the participation of two companies, 'Medytox Thailand', a sole corporation established in Thailand, and 'Medyceles', a joint venture, and holding lectures by key KOLs (Key Opinion Leaders).

On the first day of the event, Director Wook Oh of Meyrin Clinic The Hyundai Seoul Branch, one of the authors of the consensus guideline paper on 'Newlux', introduced the latest treatment method according to the consensus guideline of 'Newlux' (An Overview of the Latest Korean Consensus Guideline for Metatox® injection) and shared a full-face clinical case of botulinum toxin injection on the entire face through a video lecture session.

Next, Director Oh Myeong-jun of O& Clinic shared his know-how on improving facial contours and lip and mouth corner treatments using filler and toxin preparations under the theme of “The Secret Recipe for an Attractive Smile; Atiere, the New Filler Brand” using hyaluronic acid filler ‘Atiere.’

On the second day, Director Heo Su-jeong of Skinyoung Clinic gave a presentation on the topic of 'Guidelines & Beyond: The Next Generation of Botulinum Toxin Research&Application'. She introduced the special features of the botulinum toxin product developed by Medytox and shared her know-how on dermotoxin and calf treatment, which are widely used in Korea recently.

During the conference, Medytox garnered much attention from local Thai medical professionals by announcing plans to launch in the first half of its affiliate Newmeco’s next-generation botulinum toxin product, ‘Newlux (Thailand export name Metatox),’ and hyaluronic acid (HA) filler ‘Artiere,’ which obtained product approval in Thailand at the end of last year. ‘Newlux’ and ‘Artiere,’ which will be launched in the Thai market in the first half of this year, are positioned as premium products and plan to secure Medytox’s overwhelming market share in Thailand.

A Medytox official said, “Through this conference, we were able to confirm once again the hot interest in Medytox in Thailand,” and “We will carry out various marketing activities so that ‘Newlux’ and ‘Attier’, which will be launched soon, can quickly settle in the Thai market and achieve high growth.”

He added, “We will also lay the foundation for becoming a global brand by strengthening our position in Thailand, a major market in Southeast Asia.”